Revolade 25mg Tablet

1. Chronic idiopathic thrombocytopenia
2. Treatment of Severe Aplastic Anemia
3. Low platelet count due to ITP or HCV infection

Like other anticancer medicines, Revolade 25mg Tablet also has some common to severe side effects. These are undesired symptoms observed in the body after taking this injection. Usually, they disappear with time as the body adjusts to the medicine. These adverse effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below: Common side effects:

Diarrhea

Back pain

Appetite loss

Hair loss

headache and dizziness

Throat pain

Nausea & vomiting, muscle pain

Abdominal pain

Cold and cough

Upper respiratory tract infection

Severe side effects:

Urinary Tract Infection

Increased liver enzymes

Revolade 25mg Tablet is an oral anticancer medication that requires a prescription. It is recommended that you speak with your healthcare provider before using this tablet. As directed by your physician, take this medication for the prescribed amount of time. Eat it all at once. Avoid chewing, crushing, or breaking it. The Revolade 25mg Tablet should be taken without food.

Revolade 25mg Tablet belongs to the class of thrombopoietin (TPO) receptor agonists, consisting of the active ingredient Eltrombopag. It stimulates the bone marrow cells, called megakaryocytes. It is responsible for producing platelets in the blood. Further, Revolade Tablet prevents the loss of blood and bruising. Revolade 25mg Tablet is an anticoagulant drug belonging to the class of thrombopoietin (TPO) receptor agonists. The doctor prescribes this tablet to increase the blood platelet count caused due to chronic immune (idiopathic) thrombocytopenic purpura (ITP) or chronic hepatitis C virus (HCV) infection. ITP is an autoimmune disorder in which our immune system starts damaging our platelets. Platelets are blood cells that help in blood clotting and protecting vessels. When there is a low count of platelets in the blood, it can cause bleeding. Revolade 25mg Tablet is also used to treat severe aplastic anemia. It is a severe blood disorder that occurs when the bone marrow fails to produce enough new blood cells. It is advised not to take this tablet if you have liver disease, as Revolade 25mg Tablet can cause hepatotoxicity, increased liver enzymes, and bilirubin levels. It may worsen liver function. Your doctor must go for a weekly eye checkup for bleeding near the retina. Inform your doctor if you are taking any prescribed and non-prescribed medications. These medicines can interact with Revolade 25mg Tablet and may result in some undesirable effects. This tablet is not recommended for people under age 18. Revolade 25mg Tablet should not be given to children under age one to treat ITP.

It is advised not to miss any scheduled dosage of Revolade 25mg Tablet. In case you miss a dose, consult your doctor immediately. Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Monitor your blood platelet count regularly. Taking Revolade 25mg Tablet can drop in the count.

It may take multiple weeks or several months to observe the benefits, so do not stop taking it until your doctor asks you to do so.

It is not recommended to overdose if you miss the prescribed one. Take a dose if you miss it in less than 12 hours. If 12 hours have passed, take the next day's dose.

It is advised to take Revolade 25mg Tablet at least 2 hours before or 4 hours after eating dairy products and calcium-fortified juices.

Consult with your healthcare professional before taking Revolade 25mg Tablet if you are planning to be pregnant, planning to be pregnant or breastfeeding. It is recommended to use effective birth control methods to avoid pregnancy.

This drug is not recommended for people with hypersensitivity and allergy.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Bussel, J. B., Cheng, G., Saleh, M. N., Psaila, B., Kovaleva, L., Cheng, G., Kuter, D. J. (2007). Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 357(22), 2237–2247.

Eltrombopag Olamine (Revolade). (n.d.). Results – ENABLE 1 and ENABLE 2 trials. In NCBI Bookshelf. Retrieved from NCBI Bookshelf

European Medicines Agency (EMA). (n.d.). Revolade: usage, mechanism, and benefits in ITP and related conditions. Retrieved from the EMA website

Kuter, D. J., Bussel, J. B., Lyons, R. M., et al. (2008). Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomized, double‑blind, placebo‑controlled trial. Blood, 111(11), 5327–5333.

Medicines Information Source (MIMS HK). (n.d.). Eltrombopag in hepatic impairment: initiating at 25 mg once daily. Retrieved from MIMS Hong Kong

Park, S., Brümmendorf, T. H., Fenaux, P., et al. (2017). Eltrombopag versus placebo for low‑risk myelodysplastic syndromes with thrombocytopenia (EQoL‑MDS): Phase 1 results of a single‑blind, randomized, controlled, phase 2 superiority trial. The Lancet Haematology, 4(1), e22–e31.

Peffault de Latour, R., Bacigalupo, A., Socié, G., et al. (2022). Eltrombopag added to immunosuppression in severe aplastic anemia. New England Journal of Medicine, 386(15), 1392–1402

Rahman, A., Ahmed, T., et al. (2020). Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients: A randomized, controlled clinical trial. eClinicalMedicine, 25, 100457.

SmPC (RxReasoner). (n.d.). Eltrombopag (Revolade): dosage recommendations, including 25 mg initiation for specific populations. Retrieved from RxReasoner

Terazawa, S., et al. (2012). Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: A randomized, open‑label, phase II study. Journal of Hepatology, 56(6), 1253–1261.